Stay invested in pharma space: Sharmila Joshi

Sharmila Joshi of sharmilajoshi.com told CNBC-TV18, "Not just for Wockhardt but I would say for a whole host of pharma companies it is really very tough to sort of take a call on them at this point in time because they are facing a whole host of concerns. Wockhardt's numbers weren't good, they just declared them over the weekend which is why you are probably seeing the cut today because the numbers weren't what market was expecting plus the comments etc for their plants in Maharashtra as well as Gujarat to deal with. Though the company has indicated that all these things are in process, it is not going to be anytime soon that you will really see that clarity coming into a lot of these stocks.""Even if we were to talk of Marksans Pharma, the management did indicate that a lot of the fall that you are seeing in sales etc is due to some internal restructuring. They have hired very aggressively on the R&D front, they have a whole host of fillings etc. So, my sense actually for both stocks is that if you are reasonably long term then stay put otherwise it might be a good idea to then exit the sector altogether because in pharma you will be hard put to find a place where you can say with absolute certainty that there will be sort of safety and you can hide there while the rest of the space does badly.""A good case in point is also Biocon which was really languishing when the rest of the pharma was doing well. However, when the things that were supposed to fall in place for Biocon began to do that, you really saw the stock move to another level. So, the rise can also be equally spectacular. So, you need to really have that kind of a view and faith and have that long term view to stay invested in pharma at this point in time," she added.